The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
Nobuhiko Tanigawa - One of the best experts on this subject based on the ideXlab platform.
-
a novel method using the vio soft Coagulation System for liver resection
Surgery, 2011Co-Authors: Fumitoshi Hirokawa, Michihiro Hayashi, Yoshiharu Miyamoto, Mitsuhiko Iwamoto, Ichiro Tsunematsu, Mitsuhiro Asakuma, Tetsunosuke Shimizu, Koji Komeda, Yoshihiro Inoue, Nobuhiko TanigawaAbstract:Background The VIO soft-Coagulation System (SCS) is a new device for tissue Coagulation. The current study evaluated the efficacy of the SCS when used for liver resection. Methods The 252 patients were divided into 2 groups; in 155 patients (conventional group), liver transection was performed using an ultrasonic dissector and saline-coupled bipolar electrocautery for hemostasis. In 97 patients (SCS group), the SCS was used instead of bipolar electrocautery. Results The median blood loss and surgical time were less in the SCS group than in the conventional group (350 vs 640 mL, P = .0028; 280 vs 398 min, P P = .0039), macroscopic vascular invasion of the hepatic tumors ( P = .0088), and collagen type IV value in the sera >200 ( P = .0250) on multivariate analysis. In a subgroup analysis, in the collagen type IV value >200 subgroup, the tumor diameter >5 cm subgroup, and the inflow nonocclusion subgroup, use of the SCS decreased surgical bleeding ( P = .0120, P = .0126, and P = .0032, respectively) and surgical time ( P = .0001, P P = .0036, respectively) compared with the conventional group. Furthermore, even in the major hepatectomy group, the SCS use decreased surgical time ( P Conclusion The SCS is an effective and safe device for decreasing surgical time and surgical bleeding without increasing the rate of bile leakage and causing other complications.
Akiroterashi - One of the best experts on this subject based on the ideXlab platform.
-
Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation
Stroke, 1995Co-Authors: Takehikonagao, Makotohamamoto, Akemikanda, Toshikazutsuganesawa, Masayukiueda, Katsushikobayashi, Tokuzoumiyazaki, AkiroterashiAbstract:Background and Purpose It is generally accepted that the Coagulation System is activated in ischemic stroke and that platelet activation is involved in the pathogenesis of this disease. However, little is known about how and to what extent platelet activity participates in Coagulation System enhancement. We evaluated the hemostatic condition, especially with regard to platelet function and the Coagulation System, within 3 days of onset of acute stroke. The study participants were limited to elderly patients with cardioembolic stroke due to nonvalvular atrial fibrillation. Methods Seventeen elderly patients with acute cardioembolic stroke due to nonvalvular atrial fibrillation were investigated. Within 3 days of stroke onset, β-thromboglobulin (BTG), platelet factor 4 (PF4), thrombin-antithrombin III complex (TAT), and d-dimer from arterial blood were carefully evaluated in these patients. Blood samples from 19 healthy age- and sex-matched control subjects were also examined. Results The two studied marker...
Akiro Terashi - One of the best experts on this subject based on the ideXlab platform.
-
Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation
Stroke, 1995Co-Authors: Takehiko Nagao, Makoto Hamamoto, Akemi Kanda, Toshikazu Tsuganesawa, Masayuki Ueda, Katsushi Kobayashi, Tokuzou Miyazaki, Akiro TerashiAbstract:Background and Purpose It is generally accepted that the Coagulation System is activated in ischemic stroke and that platelet activation is involved in the pathogenesis of this disease. However, little is known about how and to what extent platelet activity participates in Coagulation System enhancement. We evaluated the hemostatic condition, especially with regard to platelet function and the Coagulation System, within 3 days of onset of acute stroke. The study participants were limited to elderly patients with cardioembolic stroke due to nonvalvular atrial fibrillation. Methods Seventeen elderly patients with acute cardioembolic stroke due to nonvalvular atrial fibrillation were investigated. Within 3 days of stroke onset, β-thromboglobulin (BTG), platelet factor 4 (PF4), thrombin-antithrombin III complex (TAT), and d-dimer from arterial blood were carefully evaluated in these patients. Blood samples from 19 healthy age- and sex-matched control subjects were also examined. Results The two studied markers of platelet activity did not change in the patients or the control subjects, and the between-group differences between the stroke and control groups were not statistically significant (BTG, 43.8 versus 31.9 ng/mL; PF4, 9.06 versus 5.78 ng/mL; respectively). In contrast, the two studied Coagulation-System indicators were markedly elevated in the patients compared with the control subjects (TAT, 13.8 versus 3.5 ng/mL, P
Fumitoshi Hirokawa - One of the best experts on this subject based on the ideXlab platform.
-
a novel method using the vio soft Coagulation System for liver resection
Surgery, 2011Co-Authors: Fumitoshi Hirokawa, Michihiro Hayashi, Yoshiharu Miyamoto, Mitsuhiko Iwamoto, Ichiro Tsunematsu, Mitsuhiro Asakuma, Tetsunosuke Shimizu, Koji Komeda, Yoshihiro Inoue, Nobuhiko TanigawaAbstract:Background The VIO soft-Coagulation System (SCS) is a new device for tissue Coagulation. The current study evaluated the efficacy of the SCS when used for liver resection. Methods The 252 patients were divided into 2 groups; in 155 patients (conventional group), liver transection was performed using an ultrasonic dissector and saline-coupled bipolar electrocautery for hemostasis. In 97 patients (SCS group), the SCS was used instead of bipolar electrocautery. Results The median blood loss and surgical time were less in the SCS group than in the conventional group (350 vs 640 mL, P = .0028; 280 vs 398 min, P P = .0039), macroscopic vascular invasion of the hepatic tumors ( P = .0088), and collagen type IV value in the sera >200 ( P = .0250) on multivariate analysis. In a subgroup analysis, in the collagen type IV value >200 subgroup, the tumor diameter >5 cm subgroup, and the inflow nonocclusion subgroup, use of the SCS decreased surgical bleeding ( P = .0120, P = .0126, and P = .0032, respectively) and surgical time ( P = .0001, P P = .0036, respectively) compared with the conventional group. Furthermore, even in the major hepatectomy group, the SCS use decreased surgical time ( P Conclusion The SCS is an effective and safe device for decreasing surgical time and surgical bleeding without increasing the rate of bile leakage and causing other complications.
Marina A Dobrovolskaia - One of the best experts on this subject based on the ideXlab platform.
-
nanoparticles and the blood Coagulation System part ii safety concerns
Nanomedicine: Nanotechnology Biology and Medicine, 2013Co-Authors: Anna Ilinskaya, Marina A DobrovolskaiaAbstract:Nanoparticle interactions with the blood Coagulation System can be beneficial or adverse depending on the intended use of a nanomaterial. Nanoparticles can be engineered to be procoagulant or to carry Coagulation-initiating factors to treat certain disorders. Likewise, they can be designed to be anticoagulant or to carry anticoagulant drugs to intervene in other pathological conditions in which Coagulation is a concern. An overview of the Coagulation System was given and a discussion of a desirable interface between this System and engineered nanomaterials was assessed in part I, which was published in the May 2013 issue of Nanomedicine. Unwanted pro- and anti-coagulant properties of nanoparticles represent significant concerns in the field of nanomedicine, and often hamper the development and transition into the clinic of many promising engineered nanocarriers. This part will focus on the undesirable effects of engineered nanomaterials on the blood Coagulation System. We will discuss the relationship between the physicochemical properties of nanoparticles (e.g., size, charge and hydrophobicity) that determine their negative effects on the blood Coagulation System in order to understand how manipulation of these properties can help to overcome unwanted side effects.
-
Nanoparticles and the blood Coagulation System. Part I: benefits of nanotechnology
Nanomedicine (London England), 2013Co-Authors: Anna Ilinskaya, Marina A DobrovolskaiaAbstract:Nanotechnology is proven to provide certain benefits in drug delivery by improving solubility, increasing uptake to target sites and changing pharmacokinetics profiles of traditional drugs. Since properties of many materials change tremendously at the nanoscale levels, nanotechnology is also being explored in various industrial applications. As such, nanoparticles are rapidly entering various areas of industry, biology and medicine. The benefits of using nanotechnology for industrial and biomedical applications are often tempered by concerns about the safety of these new materials. One such area of concern includes their effect on the immune System. While nanoparticle interactions with various constituents of the immune System have been reviewed before, little attention was given to nanoparticle effects on the blood Coagulation System. Nanoparticle interface with the blood Coagulation System may lead to either benefits to the host or adverse reactions. This article reviews recent advances in our understanding of nanoparticle interactions with plasma Coagulation factors, platelets, endothelial cells and leukocytes. Part I is focused on desirable interactions between nanoparticles and the Coagulation System, and discusses benefits of using nanotechnology to intervene in Coagulation disorders. Undesirable interactions posing safety concerns are covered in part II, which will be published in the June issue of Nanomedicine.